Cardio Diagnostics Holdings Inc. (CDIO) is making its first move outside the United States, and it's heading straight into one of the world's fastest-growing healthcare markets.

The company announced Thursday it's teaming up with Aimil Ltd. and Dr. Lal PathLabs Ltd to bring its PrecisionCHD coronary test to India, where heart disease has become an increasingly urgent public health challenge.

Here's why this matters: the test uses a combination of epigenetics, genetics, and artificial intelligence to detect coronary heart disease at the molecular level from a simple blood sample. That's a big deal in a country where some urban populations show heart disease rates as high as 13%.

Beyond Traditional Testing

PrecisionCHD's real advantage is its ability to catch both obstructive and non-obstructive forms of coronary heart disease that traditional angiograms frequently miss. It's the kind of early detection capability that can actually change treatment outcomes.

The partners are already working to integrate the test into Dr. Lal PathLabs' existing clinical and laboratory network, following Indian clinical guidelines. After completing integration and regulatory alignment, they're targeting broader commercial deployment in 2026.

What the Leaders Say

Cardio Diagnostics CEO and co-founder Dr. Meesha Dogan framed the partnership as advancing equitable access to cutting-edge cardiovascular care. Aimil Executive Director Dr. Mallika Kapur highlighted how the venture strengthens India's access to advanced heart diagnostics, while Dr. Lal PathLabs CEO Shankha Banerjee emphasized the test's potential to help clinicians detect disease earlier and personalize treatments.

Cardio Diagnostics shares dropped 15.77% to $2.35 on Thursday, hitting a new 52-week low.